Skip to main content
. 2024 Apr 26;5(6):821–833. doi: 10.34067/KID.0000000000000448

Table 2.

Area under the receiver-operating characteristic curve for AKI biomarkers measured during cisplatin therapy to predict CKD and hypertension at 3 months post-cisplatin

Biomarker and Time of Collection AUC (95% CI) to Predict 3-mo CKDa,b AUC (95% CI) to Predict 3-mo HTNc,d
NGAL, ng/mg creatinine
 EV preinfusion 0.55 (0.44 to 0.66) 0.47 (0.31 to 0.62)
 EV postinfusion 0.58 (0.47 to 0.69) 0.48 (0.33 to 0.62)
 EV discharge 0.65 (0.54 to 0.75)e 0.56 (0.36 to 0.75)
 LV preinfusion 0.53 (0.40 to 0.65) 0.53 (0.36 to 0.70)
 LV postinfusion 0.60 (0.48 to 0.72) 0.48 (0.29 to 0.66)
 LV discharge 0.57 (0.44 to 0.69) 0.41 (0.23 to 0.59)
KIM-1, pg/mg creatinine
 EV preinfusion 0.62 (0.51 to 0.72)e 0.38 (0.22 to 0.54)
 EV postinfusion 0.59 (0.48 to 0.69) 0.58 (0.43 to 0.73)
 EV discharge 0.65 (0.55 to 0.76)e 0.53 (0.34 to 0.71)
 LV preinfusion 0.57 (0.45 to 0.70) 0.49 (0.25 to 0.72)
 LV postinfusion 0.61 (0.49 to 0.72) 0.64 (0.45 to 0.82)
 LV discharge 0.42 (0.30 to 0.55) 0.59 (0.41 to 0.77)
TIMP-2×IGFBP-7, (ng/ml) 2 /1000
 EV preinfusion 0.48 (0.38 to 0.59) 0.70 (0.60 to 0.80)e
 EV postinfusion 0.58 (0.47 to 0.69) 0.59 (0.43 to 0.74)
 EV discharge 0.58 (0.48 to 0.69) 0.46 (0.29 to 0.62)
 LV preinfusion 0.61 (0.49 to 0.72) 0.61 (0.44 to 0.78)
 LV postinfusion 0.60 (0.48 to 0.72) 0.41 (0.25 to 0.57)
 LV discharge 0.43 (0.31 to 0.55) 0.47 (0.33 to 0.61)
NGAL (ng/mg creatinine) and KIM-1 (pg/mg creatinine)
 EV preinfusion 0.62 (0.52 to 0.73)e 0.44 (0.29 to 0.60)
 EV postinfusion 0.58 (0.47 to 0.69) 0.57 (0.41 to 0.72)
 EV discharge 0.67 (0.57 to 0.77)e 0.57 (0.38 to 0.75)
 LV preinfusion 0.52 (0.40 to 0.65) 0.58 (0.38 to 0.79)f
 LV postinfusion 0.62 (0.50 to 0.74) 0.60 (0.40 to 0.80)
 LV discharge 0.57 (0.45 to 0.70)f 0.58 (0.40 to 0.77)
NGAL (ng/mg creatinine) and TIMP-2×IGFBP-7 (ng/ml) 2 /1000
 EV preinfusion 0.59 (0.48 to 0.69) 0.71 (0.62 to 0.80)f
 EV postinfusion 0.57 (0.46 to 0.68) 0.58 (0.42 to 0.74)
 EV discharge 0.65 (0.54 to 0.76)e 0.53 (0.35 to 0.72)
 LV preinfusion 0.63 (0.51 to 0.75)e 0.61 (0.43 to 0.78)
 LV postinfusion 0.60 (0.48 to 0.72) 0.52 (0.33 to 0.72)
 LV discharge 0.50 (0.38 to 0.63) 0.47 (0.33 to 0.60)
KIM-1 (pg/mg creatinine) and TIMP-2×IGFBP-7 (ng/ml) 2 /1000
 EV preinfusion 0.62 (0.52 to 0.73)e 0.70 (0.59 to 0.80)f
 EV postinfusion 0.59 (0.48 to 0.70) 0.61 (0.46 to 0.76)
 EV discharge 0.65 (0.54 to 0.75)e 0.50 (0.32 to 0.68)
 LV preinfusion 0.66 (0.54 to 0.77)e 0.69 (0.55 to 0.84)f
 LV postinfusion 0.61 (0.49 to 0.73) 0.65 (0.47 to 0.83)
 LV discharge 0.46 (0.33 to 0.58) 0.66 (0.49 to 0.83)

Results stratified by time of cisplatin infusion. AUC, area under the curve; CI, confidence interval; EV, early visit; HTN, hypertension; IGFBP-7, insulin-like growth factor-binding protein 7; KIM-1, kidney injury molecule-1; LV, late visit; NGAL, neutrophil gelatinase-associated lipocalin; TIMP-2, tissue inhibitor of metalloproteinase-2.

a

For CKD analyses, including neutrophil gelatinase-associated lipocalin or kidney injury molecule-1, 118 patients were included. Early visit preinfusion: n=113, early visit postinfusion: n=113, early visit discharge: n=109, late visit preinfusion: n=89, late visit postinfusion: n=92, late visit discharge: n=85.

b

For CKD analyses, including tissue inhibitor of metalloproteinase-2×insulin-like growth factor-binding protein 7, 118 patients were included. Early visit preinfusion: n=117, early visit postinfusion: n=116, early visit discharge: n=111, late visit preinfusion: n=91, late visit postinfusion: n=93, late visit discharge: n=87.

c

For hypertension analyses, including neutrophil gelatinase-associated lipocalin or kidney injury molecule-1, 125 patients were included. Early visit preinfusion: n=120, early visit postinfusion: n=121, early visit discharge: n=116, late visit preinfusion: n=98, late visit postinfusion: n=99, late visit discharge: n=95.

d

For hypertension analyses, including tissue inhibitor of metalloproteinase-2×insulin-like growth factor-binding protein 7, 125 patients were included. Early visit preinfusion: n=124, early visit postinfusion: n=124, early visit discharge: n=118, late visit preinfusion: n=100, late visit postinfusion: n=100, late visit discharge: n=96.

e

Area under the curves: 95% confidence interval did not cross 0.50.

f

Statistically different than area under the curve of one biomarker alone as per the DeLong method.